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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness of ultrasound as treatment for CRS.
B A C K G R O U N D
Description of the condition
Definition of chronic rhinosinusitis (CRS)
Rhinosinusitis is defined as “inflammation of the nose and the
paranasal sinuses characterised by two or more symptoms, one of
which should be either nasal blockage/obstruction/congestion or
nasal discharge (anterior or posterior nasal drip) with/without fa-
cial pain or pressure, reduction or loss of smell, and either endo-
scopic signs of nasal polyps, and/or mucopurulent discharge pri-
marily from middle meatus and/or oedema/mucosal obstruction
primarily in middle meatus and/or CT changes (mucosal changes
within the ostiomeatal complex and/or sinuses)” (EPOS state-
ment: Fokkens 2012).
When the symptoms have not completely resolved in 12 weeks or
more, the disease is defined as chronic (Fokkens 2012). In some
cases of CRS, nasal polyps can be found. A variety of factors con-
tribute to the development of CRS and many studies have been
conducted to find the best treatment. Several factors may predis-
pose people to CRS, including infection, allergy and asthma, im-
paired mucociliary clearance, hormonal changes (e.g. pregnancy)
and genetic factors (Fokkens 2012; Tan 2010). To date, there is no
evidence of an aetiological correlation between anatomic variation
of the paranasal sinuses and CRS (Fokkens 2012). However, a re-
view has suggested that the underlying anatomy of sinus drainage,
leading to ostial obstruction, is one exacerbating factor in CRS
(Timperley 2010). Another study has found that in the majority
of CRS cases, persistent inflammation could cause obstruction of
the osteomeatal complex, which could explain the pathogenesis of
CRS (Tan 2010). One of the barriers to effective CRS treatment
is the ’bacterial biofilm’, an extracellular matrix or ’film’ which
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covers and protects the bacteria, and which might later lead to a
recurrence of CRS (Ansari 2007; Fokkens 2012; Harvey 2007).
Diagnosis
Diagnosis of CRS requires a systematic examination starting with
assessment of the symptoms and supported by physical, nasal en-
doscopic and radiological examination (e.g. computerised tomog-
raphy (CT) scan) (Tan 2010).
Prevalence
CRS is one of the most common healthcare problems worldwide.
It has a significant impact on quality of life and impairs physical
and social function. Although there are few epidemiological stud-
ies of CRS and its definition varies between studies, estimates of
prevalence range from 5% to 15% in the urban population (IRAB
1997). In the United States, the prevalence of CRS was found to
be 2% when diagnosed by doctors and identified by ICD-9 codes
(Shashy 2004); based on the National Health Interview Survey
this increased to 14% to 16% (Benson 1998; Cherry 2000). A
study in Korea showed the overall prevalence of CRS to be approx-
imately 7% and that it increases with age (Kim 2011). To date
there have unfortunately been few epidemiological studies con-
cerning the prevalence and incidence of CRS without nasal polyps
(CRSsNP) and with nasal polyps (CRSwNP) (Fokkens 2012).
Due to the changing patterns of antibiotic resistance, epidemi-
ological studies of the causal pathogens in CRS are important.
One study conducted in Singapore found the predominant cul-
tures to be Staphylococcus aureus and Haemophilus influenza (H.
influenzae). Another study of 83 CRS patients in the USA found
culture results for coagulase-negative staphylococci (31%), fol-
lowed by H. influenzae (25%), Streptococcus pneumoniae (12%),
Moraxella catarrhalis (10%), Pseudomonas aeruginosa (7%), alpha-
haemolytic streptococci (5%) and Staphylococcus aureus (3%). This
study concluded that sensitivity testing and culture-directed ther-
apy are needed to support treatment decision-making in CRS
(Chan 2001). Further studies are needed to assess the reasons for
antibiotic treatment failure in CRS that may be due to complex
interactions between other pathogens (Chin 2010).
Treatment
Nasal corticosteroids and broad-spectrum antibiotics, particularly
macrolides, are commonly given as therapies for CRS (Fokkens
2012). The EPOS statement reviewed the adverse effects related to
the use of nasal corticosteroids (e.g. nasal irritation, bleeding and
dryness) and the long-term use of antibiotics (e.g. gastrointestinal
problems, rash and reversible liver dysfunction) (Fokkens 2012).
Another major problem with the long-term use of antibiotics is
the potential development of resistance. Regular follow-up resis-
tance and culture tests, usually every three months, are required
to monitor this (Fokkens 2012). A Cochrane review of systemic
antibiotics for CRS concluded that more trials are needed to eval-
uate both low-dose and long-term therapy (Piromchai 2011).
Functional endoscopic sinus surgery (FESS) is a potential therapy
for CRS if medical treatment is unsuccessful, however few ran-
domised controlled trials (RCTs) have been conducted to compare
the efficacy of FESS with other medical therapies. A Cochrane
systematic review concluded that FESS does not provide addi-
tional benefit in decreasing the symptoms of CRS (Khalil 2006).
A new surgical technique in CRS treatment is endoscopic balloon
sinus ostial dilation, as one of the causes of CRS is the impair-
ment of the sinus drainage pathway of the osteomeatal complex,
caused by persistent inflammation (Rocha 2011; Tan 2010). As
a persistent reduction in mucosal inflammation is an important
step in the treatment of CRS, the balloon is used to compress
the inflamed mucosa and dilate the ostium of the sinus. However,
a Cochrane review concluded that more randomised controlled
trials are needed to assess the effectiveness and complications of
this technique adequately (Ahmed 2011). Some minor complica-
tions associated with these procedures have been reported. Two
studies have reported that 15.4% of patients experienced minor
complications related to FESS: epistaxis (nosebleeds), sinus infec-
tion, stenosis (narrowing) of themiddlemeatal antrostomy and in-
tranasal synechiae (adhesions) (Fairley 1993; Ragab 2004). Func-
tional endoscopic sinus surgery requires the skills of a specialised
rhinologist in order to avoid recurrence and complications and
also specific equipment that may not be available in many settings.
In studies of endoscopic balloon sinus ostial dilation, no major
complications were found, however a common minor complica-
tion is synechiae (Ahmed 2011).
Description of the intervention
Ultrasound is one of the treatment modalities that is proposed
for CRS. It is commonly used in physiotherapy to promote tissue
repair, relieve muscle and joint pain, and reduce inflammation,
but it has only recently been used in the treatment of rhinosinusitis
(Ansari 2007; Baker 2001; Rocha 2011).
The cheek is the most common location for ultrasound applica-
tion, based on the understanding that themaxillary sinuses appear
to be the most common site for rhinosinusitis (Kormos 2009). In
addition, adequate ciliary function is needed in the maxillary si-
nuses (as well as a sufficiently low viscosity of paranasal sinus secre-
tions) because the direction of drainage is against gravity (Leung
2008). Based on this pathophysiology, the ultrasound applicator
is moved over the facial skin overlying the affected sinuses (e.g.
maxillary and frontal sinuses) for short durations (Kormos 2009).
In three studies of CRS treatment, therapeutic ultrasound was
applied at a low intensity (0.5 to 1 W/cm²) (Ansari 2007; Naghdi
2008; Rocha 2011). We have not identified any studies that have
used higher intensities.
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How the intervention might work
The ultrasound waves penetrate the tissue on the way to the tar-
get organ and have two mechanisms of action (thermal and non-
thermal), which may potentially work synergistically to reduce
nasal symptoms (nasal blockage and secretions) (Schortinghuis
2003).The thermal effects may work by enhancing metabolic ac-
tivity and circulation within the nasal tissue. The vibration cre-
ated by the non-thermal mechanism may alter the consistency of
nasal secretions. The intensity of the ultrasound treatment may
also influence its impact, with potential beneficial effects at low
intensities but with high intensities having the potential to damage
exposed cells and tissues (Ansari 2007; Baker 2001; Rocha 2011).
It has also been proposed that ultrasound might disrupt the extra-
cellular matrix bonds of bacterial biofilms, reducing their protec-
tive effect. It has been suggested that therapeutic ultrasound and
antibiotics might therefore potentially act together in the treat-
ment of CRS (Bartley 2009).
A critical review has described negative side effects caused by high-
intensity therapeutic ultrasound in the maxillofacial region for
the treatment of soft-tissue and temporomandibular disorders,
whereas low-intensity ultrasound has not been found to be harm-
ful (Schortinghuis 2003). A randomised controlled trial of ul-
trasound compared to antibiotics in acute bacterial rhinosinusi-
tis showed mild adverse effects consisting of nausea/stomach pain
and headache (H s ien 2010). Young et al, in preliminary ob-
servations (a clinical trial with a pre-test post-test study design),
reported one adverse event, which was the development of acute
rhinosinusitis after ultrasound therapy, but no other adverse events
(Young 2010).
Why it is important to do this review
Currently, there are many treatment modalities used for the treat-
ment of CRS, including ultrasound. There are some published
clinical studies on therapeutic ultrasound used as treatment or ad-
juvant therapy for CRS, including randomised controlled trials
(Ansari 2007; Naghdi 2008; Young 2010), but no systematic re-
views. A systematic review is needed to bring to this limited evi-
dence together in one place and to assess the effectiveness of ul-
trasound for the treatment of CRS.
O B J E C T I V E S
To assess the effectiveness of ultrasound as treatment for CRS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or quasi-randomised con-
trolled trials.
Types of participants
Wewill include patients of any age (children and adults) with CRS
as defined in either:
• the European Position Paper on Rhinosinusitis and Nasal
Polyps 2012 (Fokkens 2012); or
• the Rhinosinusitis Task Force Report (RTFR 1996) and its
revision by the Sinus and Allergy Health Partnership Task Force
(including the members of RTFR 1996 from the American
Academy of Otolaryngology - Head and Neck Surgery)
(Benninger 2003); or
• sinusitis symptoms with/without endoscopic evidence and/
or radiological evidence of sinusitis for 12 weeks or more (Khalil
2006); or
• no complete resolution of rhinosinusitis symptoms after 12
weeks or more (e.g. no treatment, failed medical therapy)
(Fokkens 2012).
We will exclude patients in whom ultrasound is contraindicated,
e.g. patients with a pacemaker, cancer, pregnancy or impaired vas-
cular circulation (Batavia 2004).
Types of interventions
Intervention
The intervention is ultrasound given as a treatment for CRS, either
continuous or pulsed, at any intensity or frequency and for any
number of sessions or duration.
Comparison
The comparisons will be sham ultrasound therapy, no treatment
or other treatment.
Types of outcome measures
Primary outcomes
1. Resolution of symptoms or reduction in overall symptom
severity. Reduction in symptom severity may be measured using
visual analogue scales or a validated symptom scale, e.g.
Sinonasal Outcome Test/SNOT-20 (Piccirillo 2002).
2. Reduction in overall symptom duration.
3. Adverse effects of treatment.
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Secondary outcomes
1. Reduction in other symptom scores/scales, which are
reported by a majority of studies.
2. Recurrence of symptoms, defined as new episodes of
rhinosinusitis or the proportion of patients with recurrent
rhinosinusitis after four weeks from the start of therapeutic
ultrasound.
3. Improvement in objective measures of disease (e.g. by nasal
endoscopic or CT examination).
Search methods for identification of studies
We will conduct systematic searches for randomised controlled
trials. There will be no language, publication year or publication
status restrictions.Wemay contact original authors for clarification
and further data if trial reports are unclear, and we will arrange
translations of papers to the English language where necessary.
Electronic searches
We will identify published, unpublished and ongoing studies
by searching the following databases from their inception: the
Cochrane Ear, Nose and Throat Disorders Group Trials Register;
the Cochrane Central Register of Controlled Trials (CENTRAL,
The Cochrane Library); PubMed; EMBASE; CINAHL; LILACS;
KoreaMed; IndMed; PakMediNet; CAB Abstracts; Web of Sci-
ence; BIOSIS Previews and AMED. We will search the trials reg-
istries ISRCTN, ClinicalTrials.gov and ICTRP to locate any on-
going unpublished trials.
We will model search strategies for databases on the one designed
for CENTRAL (Appendix 1). Where appropriate, we will com-
bine subject strategies with adaptations of the highly sensitive
search strategy designed by The Cochrane Collaboration for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b (Handbook 2011).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. We will search
PubMed, TRIP database, The Cochrane Library and Google to re-
trieve existing systematic reviews relevant to this systematic review,
so that we can scan their reference lists for additional trials. We
will search for conference abstracts using the Cochrane Ear, Nose
and Throat Disorders Group Trials Register.
Data collection and analysis
Selection of studies
Two authors (RR and YP) will analyse the titles and abstracts from
the searches.We will acquire the full text of studies that potentially
meet the eligibility criteria. We will also obtain full-text articles if
eligibility of the study cannot be determined due to insufficient in-
formation supplied in the abstract or in the absence of an abstract.
The same two authors will independently assess study eligibility
from the full text to ensure they meet the inclusion criteria for the
review. We will resolve any disagreements over which studies to
include by discussion and consensus or if disagreement cannot be
resolved by these methods, we will consult a third author (EB).
Where clarification is required, we will contact the study authors
to request the relevant information. We will translate studies re-
ported in non-English language journals before assessment.Where
more than one publication of a study exists, we will group reports
together and use the publication with the most complete data in
the analyses.Where relevant outcomes are only published in earlier
versions, we will use these data. We will highlight any discrepancy
between published versions.
We will document reasons for the exclusion of studies.
Data extraction and management
Two review authors (RR and ES) will independently extract data,
using a standard data extraction form developed by the review
authors for the purpose of the review. The extraction form includes
the following information:
1. Sources: year of publication, citation and contact details.
2. Methods: study design, randomisation procedure,
allocation, blinding (participants, people administering
treatment, outcome assessors), duration of study, analysis
method.
3. Participants: number, setting (primary or referral centres),
diagnostic criteria of CRS, age and sex.
4. Interventions: interventions (intensity, frequency, exposure
mode, duration), comparison group treatment given.
5. Outcomes: outcomes specified above, any other outcomes
assessed in the trial, other events, length of follow-up.
6. Results: number of participants allocated to each
intervention group and also for each outcome and time of
assessment specified above, including a measure of variation.
Assessment of risk of bias in included studies
JB and ISW will undertake assessment of the risk of bias of the
included trials independently, with the following taken into con-
sideration, as guided by theCochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011):
1. random sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
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6. selective reporting (reporting bias);
7. other sources of bias.
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.2
(RevMan 2012), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias. As
blinding of study participants is not possible, and the study out-
comes are likely to be patient-reported, we will pay particular at-
tention to the choice of comparator. In these circumstances, sham
ultrasound will introduce less bias than a no treatment control
group.
Measures of treatment effect
If possible, we will summarise data in meta-analyses, which we
will perform according to the intention-to-treat (ITT) principle.
This means that the number of participants randomised will be
used as the denominator for each outcome. There will be three
comparisons made in the following way(s):
1. ultrasound versus sham ultrasound; and/or
2. ultrasound versus no treatment; and/or
3. ultrasound versus other active treatment.
If study characteristics and observed heterogeneity suggest that it
is plausible to pool the comparisons of sham ultrasound and no
treatment, then we will show these as subgroups with an overall
estimate also calculated.
For dichotomous outcomes (proportion with resolution of symp-
toms, proportion with adverse effects, proportion with recur-
rence), we will express results as risk ratios (RR), with 95% con-
fidence intervals (CI). For statistically significant results we will
calculate the number needed to treat to benefit (NNTB) and the
number needed to treat to harm (NNTH). Where continuous
scales of measurement are used to assess the effects of treatment
(reduction of symptom severity and symptom duration), we will
use themean difference (MD) or the standardised mean difference
(SMD) if different scales have been used.
We recognise that some studies are likely to present results as mean
change scores. If so, we will present the studies with a mean change
as a subgroup separately from the other studies, but will combine
the subgroups into an overall estimate. If the standard deviation
of the change scores is not given in a small proportion of studies,
we will impute them where possible, either using the standard
deviation from similar studies, or using the correlation coefficient
between baseline and final measurements if sufficient information
is presented in the articles (Handbook 2011).
Unit of analysis issues
We do not expect any trials in this area to utilise a cross-over or
cluster-randomised design.
For studies of more than two intervention groups, where more
than two of the groups are eligible for this review, we will follow
the methods of the Cochrane Handbook for Systematic Reviews of
Interventions. That is, in studies with more than one control group
or more than one intervention group, we will combine the results
of the control or intervention groups respectively (Handbook
2011).
Dealing with missing data
Where possible, we will use intention-to-treat analyses of each in-
cluded study to extract data. That is, each participant will be in-
cluded in the group to which they were randomised and all ran-
domised participants will be included in the analysis. Otherwise,
we will use an available case analysis. That is, each participant for
whom the outcome was measured will be included in the group
to which they were randomised. We will explore the effect of any
missing data using sensitivity analysis (Handbook 2011).
Assessment of heterogeneity
We will assess the presence of heterogeneity in two steps. First,
we will assess obvious heterogeneity at face value by comparing
populations, settings, interventions and outcomes before deciding
whether it is appropriate to pool studies. Second, we will assess
statistical heterogeneity by means of the I² statistic. Thresholds for
the interpretation of the I² statistic can be misleading, since the
importance of inconsistency depends on several factors.We plan to
use the guide to interpretation as outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions: 0% to 40% might not
be important; 30% to 60% may represent moderate heterogene-
ity; 50% to 90% may represent substantial heterogeneity; 75% to
100% considerable heterogeneity (Handbook 2011).
Assessment of reporting biases
If sufficient studies are included, we will use funnel plots to assess
for the potential existence of small study publication bias. We will
report the conflict of interest declaration of the authors where
available (Handbook 2011).
Data synthesis
Where it is reasonable to assume a single pooled effect, we will use
a fixed-effect model to pool data. If a single pooled effect is not
plausible, due to variation in populations and interventions, or
important substantial heterogeneity, we will use a random-effects
model (DerSimonian and Laird method) (Handbook 2011).
We will use RevMan 5.2 for statistical analysis (RevMan 2012).
Subgroup analysis and investigation of heterogeneity
If sufficient studies are included, we plan to subgroup the studies
in the following way(s):
1. children and adults;
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2. CRSsNP (CRS without nasal polyps) and CRSwNP (CRS
with nasal polyps);
3. pulsed and continuous ultrasound;
4. low-frequency and high-frequency ultrasound;
5. low-intensity and high-intensity ultrasound.
If heterogeneity is discovered at the analysis stage, which suggests
other subgroup analyses, we will make it clear that these were not
planned at the protocol stage (Handbook 2011).
Sensitivity analysis
Weplan to conduct sensitivity analysis to determine the robustness
of results to studies at high risk of bias (Handbook 2011).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 rhinosinusitis or nasosinusitis or sinusitis or pansinusitis or ethmoiditis or sphenoiditis
#3 kartagener* and syndrome*
#4 inflamm* and sinus*
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Chronic Disease] explode all trees
#7 chronic or persis*
#8 #6 or #7
#9 #5 and #8
#10 MeSH descriptor: [Diathermy] explode all trees
#11 ultrasound* or ultrasonic* or diatherm*
#12 MeSH descriptor: [Ultrasonics] explode all trees
#13 MeSH descriptor: [Radio Waves] explode all trees
#14 MeSH descriptor: [Sound] explode all trees
#15 “cus” or “pus” or “liust” or 1-MHz or atomiz* or atomis* or “lfu” or “swd” or “cswd” or “pswd” or “lora”
#16 “nonthermal effect*” or “nonthermal exposure” or “ thermal effect*” or “thermal exposure” or “wave exposure” or “short wave*”
or “radio wave*” or shortwave*
#17 (pulsed or continuous) and (wave* or therapy)
#18 (acoustic* or “sound” or “high frequency” or “low frequency” or “low intensity” or elastic or sonic) and (energy or wave* or
radiation)
#19 MeSH descriptor: [Physical Therapy Specialty] explode all trees
#20 Physiotherap* or “physical therap*”
#21 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
#22 #9 and #21
C O N T R I B U T I O N S O F A U T H O R S
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• YP will contribute to search strategy development, study selection, data extraction and data entry into RevMan.
• ISW will contribute to search strategy development, ’Risk of bias’ assessment and data analysis.
• JB will contribute to ’Risk of bias’ assessment and data analysis.
• EB will contribute to protocol preparation and analysis interpretation, and also with expert opinion and independent assessment.
• PG will contribute to analysis interpretation, and also with expert opinion and independent assessment.
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